We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-2.75%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.1B
AUM Growth
+$273M
(+2%)
Cap. Flow
-$650M
Cap. Flow
% of AUM
-4.61%
Top 10 Holdings %
Top 10 Hldgs %
32.88%
Holding
703
New
–
Increased
221
Reduced
319
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$41.6M |
| 2 |
NVIDIA
NVDA
|
+$36M |
| 3 |
Intuitive Surgical
ISRG
|
+$33.8M |
| 4 |
Applied Materials
AMAT
|
+$32.4M |
| 5 |
XP
XP
|
+$31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$57.8M |
| 2 |
Johnson & Johnson
JNJ
|
+$54.9M |
| 3 |
Danaher
DHR
|
+$41.9M |
| 4 |
Microsoft
MSFT
|
+$40.7M |
| 5 |
Lam Research
LRCX
|
+$37.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.08% |
| 2 | Technology | 25.64% |
| 3 | Financials | 11.81% |
| 4 | Industrials | 7.9% |
| 5 | Materials | 7.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
WBA
626
DELISTED
Walgreens Boots Alliance
WBA
| $1.11K | ﹤0.01% |
90,202
+29,291
| +48% | +$779K |
|
627
Adicet Bio
ACET
$77.6M
| – | – |
-44,743
| Closed | -$1.74M |
|
|
AKYA
628
DELISTED
Akoya BioSciences
AKYA
| – | – |
-276,300
| Closed | -$2.04M |
|
|
AMED
629
DELISTED
Amedisys
AMED
| – | – |
-70,000
| Closed | -$6.4M |
|
630
Array Technologies
ARRY
$740M
| – | – |
-121,945
| Closed | -$2.76M |
|
631
Atkore
ATKR
$2.41B
| – | – |
-15,727
| Closed | -$2.45M |
|
632
AstraZeneca
AZN
$269B
| – | – |
-186,102
| Closed | -$26.6M |
|
633
Brookfield Asset Management
BAM
$75.6B
| – | – |
-7,489
| Closed | -$245K |
|
634
Credicorp
BAP
$30.5B
| – | – |
-101,900
| Closed | -$15M |
|
635
Bath & Body Works
BBWI
$3.97B
| – | – |
-9,923
| Closed | -$372K |
|
636
BorgWarner
BWA
$12.8B
| – | – |
-4,845
| Closed | -$209K |
|
637
Campbell Soup
CPB
$6.85B
| – | – |
-126,192
| Closed | -$5.77M |
|
638
Crocs
CROX
$6.63B
| – | – |
-11,330
| Closed | -$1.27M |
|
639
Cenovus Energy
CVE
$54.2B
| – | – |
-17,512
| Closed | -$298K |
|
640
Franco-Nevada
FNV
$41.3B
| – | – |
-3,036
| Closed | -$433K |
|
641
Fox Class B
FOX
$22.1B
| – | – |
-10,920
| Closed | -$348K |
|
642
Futu Holdings
FUTU
$14.3B
| – | – |
-40,692
| Closed | -$1.62M |
|
643
Liberty Media Series A
FWONA
$23.4B
| – | – |
-14,056
| Closed | -$910K |
|
644
Liberty Media Series C
FWONK
$25.5B
| – | – |
-127,015
| Closed | -$9.24M |
|
645
CGI
GIB
$15.6B
| – | – |
-2,325
| Closed | -$245K |
|
646
Lincoln National
LNC
$7.92B
| – | – |
-64,327
| Closed | -$1.66M |
|
647
Southwest Airlines
LUV
$21.7B
| – | – |
-59,232
| Closed | -$2.14M |
|
648
Macy's
M
$6.51B
| – | – |
-639,858
| Closed | -$10.3M |
|
|
MRSN
649
DELISTED
Mersana Therapeutics
MRSN
| – | – |
-96,619
| Closed | -$7.95M |
|
650
Maravai LifeSciences
MRVI
$972M
| – | – |
-100,000
| Closed | -$1.24M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2023 Portfolio in Review
As of Q3 2023, Candriam SCA held 703 positions worth $14.1B, up 2% from $13.8B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Candriam SCA withdrew a net $650M in Q3 2023, closing 43 positions and reducing 319 holdings. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $31.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA added an estimated $41.6M to Amgen.
- Candriam SCA added most to Amgen in Q3 2023, an estimated $41.6M increase.
- Candriam SCA's biggest Q3 2023 reduction was Visa, cutting an estimated $57.8M.
- Candriam SCA fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $31.7M.
- Candriam SCA's ten largest holdings make up 33% of its $14.1B portfolio in Q3 2023.
- Candriam SCA opened 0 new positions and closed 43 in Q3 2023.
- Candriam SCA's portfolio value rose 2% quarter-over-quarter to $14.1B.
Based on Candriam SCA's 13F filing for Q3 2023, filed 13 Nov 2023.